Clinical trials: Asthma Patients
Asthma
Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
- Trial name
- NCT00400855
- Testing
- Fluticasone propionate
- Where
- 2 sites in New Zealand
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09.
- Trial name
- Oraltek-58 (NCT07348302)
- Testing
- Allergen Immunotherapy Extract
- Where
- 19 sites in Argentina, China and 2 more
- Volunteers
- 736 people
- Sponsor
- Inmunotek S.L.
Asthma
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use…
- Trial name
- Epi-Asthma (NCT05169619)
- Where
- 37 sites in Portugal
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT07904195
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Asthma
A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
A study involving primary data collection within real-world settings of participants who initiate treatment with tezepelumab for severe uncontrolled asthma.
- Trial name
- NCT05677139
- Testing
- None (Observational Study)
- Where
- 58 sites in Austria, Belgium and 7 more
- Volunteers
- 513 people
- Sponsor
- AstraZeneca
Asthma
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an…
- Trial name
- NCT01545440
- Testing
- lebrikizumab
- Where
- 71 sites in United States, Australia
- Volunteers
- 258 people
- Sponsor
- Genentech, Inc.
Asthma
A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)
A study to assess the clinical effect of montelukast sodium with concomitant administration of inhaled budesonide in asthmatic patients.
- Trial name
- NCT00140946
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks
- Volunteers
- 546 people
- Sponsor
- Organon and Co
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00463697
- Testing
- GW642444H (100mcg), GW642444M (25, 100 & 400 mcg)
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study
SevEos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the Gulf region.
- Trial name
- SevEos (NCT03387722)
- Where
- 2 sites in Oman, United Arab Emirates
- Volunteers
- 253 people
- Sponsor
- AstraZeneca
Pediatric Respiratory Diseases, Asthma
Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients
This observational clinical trial is designed to confirm whether RESP™ Biosensor could be deployed to support clinical decision making in challenging pediatric cases, minimize clinician-to-clinician variability in lung sound…
- Conditions
- Pediatric Respiratory Diseases, Asthma, RSV Infection, COVID-19
- Trial name
- NCT05661422
- Testing
- RESP™ Biosensor
- Where
- United States
- Sponsor
- Strados Labs, Inc.
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Asthma
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
- Trial name
- NCT00330070
- Testing
- IPL512,602 20 mg once daily
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Inflazyme Pharmaceuticals Ltd
Asthma
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
A randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week run-in period followed by a 6-week treatment period of the placebo, Test product (Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5…
- Trial name
- NCT03015259
- Testing
- Budesonide/Formoterol fumarate dihydrate, Symbicort
- Where
- 95 sites in United States
- Volunteers
- 1,762 people
- Sponsor
- Kindeva Drug Delivery
Asthma
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
The purpose of this study was to evaluate whether 2 puffs of fixed combination of aerosolized 120 mcg salbutamol sulphate (equivalent to 100 mcg of the base) + 20 mcg ipratropium bromide confers significant additional protection…
- Trial name
- NCT02182713
- Testing
- Salbutamol sulfate/Ipratropium bromide, Salbutamol
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01868061
- Testing
- Lebrikizumab
- Where
- 232 sites in United States, Argentina and 24 more
- Volunteers
- 1,068 people
- Sponsor
- Hoffmann-La Roche
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.
- Trial name
- NCT00605306
- Testing
- indacaterol maleate / mometasone furoate
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Novartis
Asthma
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved…
- Trial name
- NCT00941798
- Testing
- QMF149 Twisthaler®, Mometasone Twisthaler®
- Where
- 146 sites in United States, Brazil and 7 more
- Volunteers
- 2,283 people
- Sponsor
- Novartis Pharmaceuticals